Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 153-159

  Bergstrom P ^a   Johnsson, A ^b   Cavallin Stahl E ^b   Bergenheim, T ^a   Henriksson, R ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

amphotericin B; chemotherapy; cisplatin; DNA adducts; glioma; renal toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CISPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG CYTOTOXICITY; GLIOMA; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHOTERICIN B; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; DRUG INTERACTIONS; GLIOMA; KIDNEY TUBULAR NECROSIS, ACUTE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED STRAINS;

EID: 0031038330     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00339-5     Document Type: Article

References (34)

1. 1. Stewart DJ, Matshela J, Eapen L, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 1994, 28, 531-542.
2. 2. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacal 1990, 40 (10), 2353-2362.
3. 3. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990, 2, 275-280.
4. 4. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood 1993, 81, 151-157.
5. 5. Kondo S, Yin D, Morimura T, Kubo H, Nakatsu S, Takeuchi J. Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 1995, 71, 282-289.
6. 6. Timmer-Bosscha H, Mulder NH, de Vries EGE. Modulation of cis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer 1992, 66, 227-238.
7. 7. Bergström P, Grankvist K, Holm S, Henriksson R. Effects of antimicrobial drugs on the cytotoxicity of epirubicin, bleomycin, estramustine and cisplatin. Anticancer Res 1991, 11, 1039-1044.
8. 8. Morikage T, Bungo M, Inomata M, et al. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res 1991, 83, 747-751.
9. 9. Kikkawa F, Kojima M, Ogushi H, et al. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res 1993, 13, 891-896.
10. 10. Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y, Saijo N. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 1993, 53, 3302-3307.
11. 11. Kojima M, Kikkawa F, Ogushi H, et al. Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo. Eur J Cancer 1994, 30A(6), 773-778.
12. 12. Bergenheim AT, Elfversson J, Gunnarsson P-O, Edman K, Hartman M, Henriksson R. Cytotoxic effect and uptake of estramustine in a rat glioma model. Int J Oncol 1994, 5, 293-299.
13. 13. Blommaert. Detection of platinum-DNA adducts. Doctoral thesis. The Netherlands Cancer Institute, Amsterdam 1996.
14. 14. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, den Engelse L. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum (II) and cis-diamine (1,1-cyclobutanedicarboxylato) platinum (II) with DNA in rodent tissues. Cancer Res 1987, 47, 6719-6725.
15. 15. Johnsson A, Olsson C, Andersson H, Cavallin-Ståhl E. Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 1994, 17, 142-150.
16. 16. Bacus JW, Grace LJ. Optical microscope system for standardized cell measurements and analyses. Applied Optics 1987, 26, 3280-3293.
17. 17. Wijsman JK, Jonker RR, Keijzer R, De Velde DJH, Cornelisse CJ, van Dierendonk JK. A new method to detect apoptosis in paraffin sections: in situ end-labelling of fragmented DNA. J Histochem Cytochem 1993, 41, 7-12.
18. 18. Dive C, Wyllie AH. Apoptosis and cancer chemotherapy. In Hickman JA and Tritton TT, eds. Frontiers in Pharmacology: Cancer Chemotherapy. Blackwell Scientific Publications, Oxford, 1993, 21-26.
19. 19. Tounekti O, Pron G, Belehradek JRJ, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993, 53, 5462-5469.
20. 20. Pinzani V, Bressole F, Haug IJ, Galtier M, Blayac JP, Balmès P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994, 35, 1-9.
21. 21. Yasumasu T, Ueda T, Uozumi J, Mihara Y, Koikawa Y, Kumazawa J. Ultrastructural alterations and DNA synthesis of renal cell nuclei following cisplatin or carboplatin injection in rats. J Pharmacy Pharmacol 1992, 44(1), 885-887.
22. 22. Johnsson A, Olsson C, Nygren O, Nilsson M, Serving B, Cavallin-Ståhl E. Pharmacokinetics and tissue distribution in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 1995, 37, 23-31.
23. 23. Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC. Cis-diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal and tumor tissues of male and female rats. Cancer Res 1987, 47, 718-722.
24. 24. Fichtinger-Schepman AMJ, Vendrik CPJ, van Dijk-Knijnenburg WCM, et al. Platinum concentration and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res 1989, 49, 2862-2867.
25. 25. Phelps JS, Gandolphi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: in vitro studies with precision cut rabbit renal cortical slices. Toxicol Appl Pharmacol 1987, 90, 510-512.
26. 26. Bodey GP. Topical and systemic antifungal agents. Med Clin North Am 1988, 72, 637-659.
27. 27. Hay RJ. Liposomal amphotericin B, AmBisome. J Infect 1994, 28 (Suppl. 1), 35-43.
28. 28. Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982, 42, 2474-2479.
29. 29. Vallbo C, Bergenheim AT, Bergh A, Grankvist K, Henriksson R. DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain suggesting an apoptotic cell death. Br J Cancer 1995, 71, 717-720.
30. 30. Cao SS, Zehn YS. Potentiation of antimetabolite antitumour activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 1989, 24, 181-186.
31. 31. Kimler BF. The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions. J Neuro-Oncol 1994, 20, 103-109.
32. 32. Gordon JA, Gattone VH. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986, 250 (6, Pt2), 991-998.
33. 33. Kaneko S, Clendenon NR, Kartha M. Experimental study in a rat brain tumor by combined treatment with cis-DDP and irradiation. Neurol Med Chir (Tokyo) 1983, 23, 917-923.
34. 34. Valeriote F, Dieckman J, Chabot G. Schedule-dependent potentiation of lomustine cytotoxicity by amphotericin B in mice. JNCI 1986, 76, 521-525.